Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
Aggen DH, Ager CR, Obradovic AZ, Chowdhury N, Ghasemzadeh A, Mao W, Chaimowitz MG, Lopez-Bujanda ZA, Spina CS, Hawley JE, Dallos MC, Zhang C, Wang V, Li H, Guo XV, Drake CG. Aggen DH, et al. Among authors: ager cr. Clin Cancer Res. 2021 Jan 15;27(2):608-621. doi: 10.1158/1078-0432.CCR-20-1610. Epub 2020 Nov 4. Clin Cancer Res. 2021. PMID: 33148676 Free PMC article.
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.
Ager CR, Zhang M, Chaimowitz M, Bansal S, Obradovic A, Rogava M, Melms JC, McCann P, Spina C, Drake CG, Dallos MC, Izar B. Ager CR, et al. bioRxiv [Preprint]. 2023 Jan 2:2023.01.01.522340. doi: 10.1101/2023.01.01.522340. bioRxiv. 2023. Update in: J Immunother Cancer. 2023 Sep;11(9):e006782. doi: 10.1136/jitc-2023-006782. PMID: 36711647 Free PMC article. Updated. Preprint.
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators.
Obradovic A, Ager C, Turunen M, Nirschl T, Khosravi-Maharlooei M, Iuga A, Jackson CM, Yegnasubramanian S, Tomassoni L, Fernandez EC, McCann P, Rogava M, DeMarzo AM, Kochel CM, Allaf M, Bivalacqua T, Lim M, Realubit R, Karan C, Drake CG, Califano A. Obradovic A, et al. Cancer Cell. 2023 May 8;41(5):933-949.e11. doi: 10.1016/j.ccell.2023.04.003. Epub 2023 Apr 27. Cancer Cell. 2023. PMID: 37116491 Free PMC article.
Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial.
Ager CR, Obradovic A, McCann P, Chaimowitz M, Wang ALE, Shaikh N, Shah P, Pan S, Laplaca CJ, Virk RK, Hill JC, Jugler C, DeFranco G, Bhattacharya N, Scher HI, DeCastro GJ, Anderson CB, McKiernan JM, Spina CS, Stein MN, Runcie K, Drake CG, Califano A, Dallos MC. Ager CR, et al. medRxiv [Preprint]. 2024 Sep 11:2024.09.09.24313308. doi: 10.1101/2024.09.09.24313308. medRxiv. 2024. PMID: 39314954 Free PMC article. Preprint.
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.
Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, Ager CR, Wang ZQ, Reuben A, Cooper ZA, Ivan C, Ju Z, Nwajei F, Wang J, Davies MA, Davis RE, Wargo JA, Bhattacharya PK, Hong DS, Curran MA. Jaiswal AR, et al. Among authors: ager cr. Cancer Immunol Res. 2020 Nov;8(11):1365-1380. doi: 10.1158/2326-6066.CIR-19-0005. Epub 2020 Sep 11. Cancer Immunol Res. 2020. PMID: 32917656 Free PMC article.
29 results